41.81
0.73 (1.78%)
| Previous Close | 41.08 |
| Volume | 1,009,997 |
| Price / Sales | 2.84 |
| Price / Book | 2.32 |
| 52 Weeks Range |
| Profit Margin | 9.27% |
| Operating Margin (TTM) | -4.67% |
| Diluted EPS (TTM) | 1.11 |
| Quarterly Revenue Growth (YOY) | 4.30% |
| Quarterly Earnings Growth (YOY) | 1,204.50% |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 164.15 M |
| Levered Free Cash Flow (TTM) | 138.80 M |
| Return on Assets (TTM) | 2.76% |
| Return on Equity (TTM) | 6.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Supernus Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Relative Valuation | -5.0 |
| Financial Health | 2.7 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.07 |
Select this tab to load the latest available analysis.
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 109.15% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |